Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling

American Journal of Respiratory Cell and Molecular Biology

Volumn 44, Issue 4, 2011, Pages 500-508

  Van Rheen, Zachary ^a,b   Fattman, Cheryl ^c   Domarski, Shannon ^a   Majka, Susan ^b   Klemm, Dwight ^b   Stenmark, Kurt R ^a,b   Nozik Grayck, Eva ^a,b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Early growth response 1; Extracellular superoxide; Interstitial lung disease; Transforming growth factor

Indexed keywords

ANTIOXIDANT; BLEOMYCIN; EARLY GROWTH RESPONSE FACTOR 1; EXTRACELLULAR SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MORTALITY; MOUSE; NITROSATIVE STRESS; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; PULMONARY VASCULAR REMODELING; SYSTOLIC BLOOD PRESSURE; UPREGULATION; WILD TYPE;

ANIMALS; BLEOMYCIN; CELL PROLIFERATION; EARLY GROWTH RESPONSE PROTEIN 1; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE III; NITROSATION; OXIDATION-REDUCTION; PULMONARY ARTERY; PULMONARY FIBROSIS; STRESS, PHYSIOLOGICAL; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE;

MUS; MUS MUSCULUS;

EID: 79953753218     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0065OC     Document Type: Article

References (26)

1. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008;31:1357-1367.
2. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L152-L160. (Pubitemid 351253350)
3. Gao F, Kinnula VL, Myllarniemi M, Oury TD. Extracellular superoxide dismutase in pulmonary fibrosis. Antioxid Redox Signal 2008;10:343-354.
4. Nozik-Grayck E, Stenmark KR. Role of reactive oxygen species in chronic hypoxic pulmonary hypertension. In: Roach R, Hackett P, editors. Hypoxia and the circulation. Vol 618. New York: Springer Academics, 2007. pp. 101-112.
5. Nozik-Grayck E, Suliman HB, Majka S, Albietz J, Van Rheen Z, Roush K, Stenmark KR. Lung EC-SOD overexpression attenuates hypoxic induction of Egr-1 and chronic hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2008;295:L422-L430.
6. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 2008;294:L24-L33. (Pubitemid 351380315)
7. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005;97:967-974. (Pubitemid 41668909)
8. Champion HC, Bivalacqua TJ, D'Souza FM, Ortiz LA, Jeter JR, Toyoda K, Heistad DD, Hyman AL, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: effect on agonist-induced and flow-mediated vascular responses. Circ Res 1999;84:1422-1432. (Pubitemid 29293221)
9. Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW, Beasley MB, Hyman AL, Friedman M, Kadowitz PJ. Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol 2002;282:L1209-L1221. (Pubitemid 34654576)
10. Fattman CL, Chu CT, Kulich SM, Enghild JJ, Oury TD. Altered expression of extracellular superoxide dismutase in mouse lung after bleomycin treatment. Free Radic Biol Med 2001;31:1198-1207. (Pubitemid 33052495)
11. Bowler RP, Nicks M, Warnick K, Crapo JD. Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002;282:L719-L726. (Pubitemid 34665587)
12. Fattman CL, Chang LY, Termin TA, Petersen L, Enghild JJ, Oury TD. Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase. Free Radic Biol Med 2003;35:763-771. (Pubitemid 37329479)
13. McNamara PJ, Murthy P, Kantores C, Teixeira L, Engelberts D, van Vliet T, Kavanagh BP, Jankov RP. Acute vasodilator effects of Rhokinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am J Physiol Lung Cell Mol Physiol 2008;294:L205-L213. (Pubitemid 351253358)
14. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
15. Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005;97:95-98.
16. Banks MF, Gerasimovskaya EV, Tucker DA, Frid MG, Carpenter TC, Stenmark KR. Egr-1 antisense oligonucleotides inhibit hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts. J Appl Physiol 2005;98:732-738. (Pubitemid 40129989)
17. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, Yehualaeshet T, Lu B, Flavell RA, Milbrandt J, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med 2004;200:377-389. (Pubitemid 39031256)
18. Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G, Mori Y, Chang E, Nihijima C, Takehara K, et al. SMAD-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol 2008;173:1085-1099.
19. Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, Leof E, Varga J. A non-SMAD mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009;28:1285-1297.
20. Bhattacharyya S, Wei J, Melichian DS, Milbrandt J, Takehara K, Varga J. The transcriptional cofactor NAB2 is induced by TGF-beta and suppresses fibroblast activation: physiological roles and impaired expression in scleroderma. PLoS ONE 2009;4:e7620.
21. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, Sherrill TP, Plieth D, Neilson EG, Blackwell TS, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2009;180:657-665.
22. Inghilleri S, Morbini P, Oggionni T, Barni S, Fenoglio C. In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis. Histochem Cell Biol 2006;125:661-669.
23. Teixeira KC, Soares FS, Rocha LG, Silveira PC, Silva LA, Valenca SS, Dal Pizzol F, Streck EL, Pinho RA. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulm Pharmacol Ther 2008;21:309-316. (Pubitemid 351312673)
24. Oury TD, Day BJ, Crapo JD. Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Lab Invest 1996;75:617-636. (Pubitemid 26392794)
25. Yildirim A, Ersoy Y, Ercan F, Atukeren P, Gumustas K, Uslu U, Alican I. Phosphodiesterase-5 inhibition by sildenafil citrate in a rat model of bleomycin-induced lung fibrosis. Pulm Pharmacol Ther 2010;23:215-221.
26. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007;292:L885-L897. (Pubitemid 46608235)